Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI)

Autor:	Lisa M. Cordes, Yang-Min Ning, Mohammadhadi Bagheri, Daniel K Lee, Seth M. Steinberg, Rosa Nadal, William L. Dahut, Sumanta K. Pal, Mark N. Stein, Donald P. Bottaro, Andrea B. Apolo, Primo N. Lara, Rene Costello, Piyush K. Agarwal, Howard L. Parnes, Ryan Thompson, Paul Monk, Christian Mayfield, Amir Mortazavi
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research Chemotherapy medicine.medical_specialty Metastatic Urothelial Carcinoma Cabozantinib business.industry Genitourinary system medicine.medical_treatment Ipilimumab 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine chemistry Refractory 030220 oncology & carcinogenesis Internal medicine medicine Clinical efficacy Nivolumab business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:4528-4528
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.4528
Popis:	4528Background: Preliminaryclinical activity of CaboNivo and CaboNivoIpi has been previously reported for mUC pts and other genitourinary tumors. Here, we report longer follow-up data of CaboNivo a...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c361bbf27935b9f718307dedc3a8f0f1 https://doi.org/10.1200/jco.2018.36.15_suppl.4528 Zobrazit plný text záznamu